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Abstract
Alveolar soft-part sarcoma (ASPS) is a rare neoplasm with chromosomal translocation that results in ASPL-TFE3
fusion. It is a slow-growing lesion associated with a high incidence of pulmonary and brain metastases indicating
poor survival. We demonstrated that the ASPS metastases include also stromal myofibroblasts. These cells pro-
liferate, express smooth-muscle genes, and synthesize extracellular matrix proteins, all of which are characteris-
tics of activated myofibroblasts. The tumor cells also exhibited stromal components such as transforming growth
factor beta (TGFβ)–dependent, hypoxia-regulated cytoglobin (stellate cell activation association protein, cytg/
STAP) and prolyl 4-hydroxylase, a collagen cross-linking enzyme. The pulmonary ASPS myofibroblasts synthesize
serum response factor (SRF), a repressor of Smad3-mediated TGFβ signaling essential for myofibroblast differen-
tiation and Smad3. The phosphorylated active Smad3 was found mostly in the tumor cells. The brain tumor cells
express cytg/STAP, but in contrast to the lung metastases, they also express SRF, Smad3, and phospho-Smad3.
Halofuginone, an inhibitor of myofibroblasts’ activation and Smad3 phosphorylation, inhibited tumor development
in xenografts derived from renal carcinoma cells harboring a reciprocal ASPL-TFE3 fusion transcript. This inhibition
was associated with the inhibition of TGFβ/SRF signaling, with the inhibition of myofibroblasts’ activation, and with
the complete loss in TFE3 synthesis by the tumor cells. These results suggest that the myofibroblasts may serve
as a novel target for treatment of ASPS metastases.
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Introduction
Alveolar soft-part sarcoma (ASPS) is a rare soft tissue neoplasm that
can arise in any region of the body. In young adults, the neoplasm
often develops in the upper or lower extremities; in young children
and adolescents, the tumor commonly originates in the head and neck
where the orbit or tongue are the most favorable sites [1,2]. The neo-
plasm is characterized cytogenetically by an unbalance recurrent chro-
mosomal translocation resulting in a consistent der(17)t(X;17)(p11;
q25). This translocation results in the fusion of the ASPL gene on chro-
mosome 17 to the TFE3 gene on chromosome X [1,3]. Alveolar soft-
part sarcoma is typically a slow-growing lesion, but frequently, it is
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associated with high incidence of pulmonary and brain metastases early
in the course of the disease [4]. Treatment of ASPS patients includes
surgical resection of the primary tumor and of the metastases when pos-
sible, the use of chemotherapy, and, in some cases, the use of radiother-
apy [2,5]. The curative potential of surgery alone has remained unclear.
Local recurrences have been reported to occur in up to 20% of patients
with ASPS [6], althoughmost of the patients operatedwithwide surgical
margins did not develop local recurrence [7]. Few, if any, of the patients
showed a clinical response to chemotherapy, and chemotherapy or im-
munotherapy for metastatic tumor, including cisplatin, ifosfamide,
doxorubicin, carboplatin, methotrexate, interferon, and interleukin 2,
regimens was without any clinical response [7,8]. Tumor size, bone
involvement, and especially metastases at presentation indicate a sig-
nificantly poorer prognosis [7]. Therefore, alternative treatment ap-
proaches are needed especially for patients with a metastatic disease.
Most solid tumors consist of a mixture of neoplastic and nonneo-
plastic cells with extracellular matrix (ECM) components. This cel-
lular microenvironment directly modulates tissue architecture, cell
morphology, and cell fate [9], and the ECM–stromal cell interaction
contributes to the neoplastic phenotype [10]. The conversion of fi-
broblasts to myofibroblasts, as mediated by transforming growth fac-
tor beta (TGFβ) and its inducible transcription factor the serum
response factor (SRF), is the most prominent stromal reaction in a
large number of epithelial lesions [11–13]. After binding of TGFβ to
its receptor, signaling to the nucleus occurs predominantly by the
phosphorylation of cytoplasmatic mediators of the Smad family
[14]. The regulation of matrix proteins, in general, and of collagen
type I gene expression, in particular, involved the Smad3 signaling
pathway [15]. In addition to the major increase in ECM compo-
nents, the fibroblasts that acquire an activated phenotype are charac-
terized by expressing smooth muscle genes such as α smooth-muscle
actin (αSMA) and transgelin [16]. Smad3 directly links TGFβ signal-
ing to an SRF-associated regulatory network in controlling muscle-
specific gene transcription [17]. The myofibroblasts are associated with
the tumor cells at all stages of cancer progression [18], and in various
malignancies, tumor-dependent differentiation of fibroblasts toward
myofibroblasts further promotes neoplastic progression [19–21]. It is
well established that collagen type I, the major ECM component pro-
duced by myofibroblasts, not only functions as a scaffold for the tis-
sue but also regulates the expression of genes associated with cellular
signaling and metabolism, gene transcription, and translation, thus af-
fecting fundamental cellular processes that are essential for tumor pro-
gression. For example, collagen type I was found to be a signal for
invasion, and its intratumoral expression level has been associated with
increased tumor invasiveness [22]. Stellate cell activation association
protein, also known as cytoglobin (cygb/STAP) is another TGFβ-
regulated and collagen-related gene expressed by the myofibroblasts
[23]. Although its specific role is yet to be elucidated, a potential role
in the detoxification of reactive oxygen species in tumors and other
pathologies has been suggested [24,25].
In this study, we demonstrated the presence of activated myofibro-
blasts and demonstrated the existence of the TGFβ/SRF–dependent
Smad3 pathway in human ASPS lung and brain metastases. In xeno-
grafts produced by cells harboring the reciprocal ASPL-TFE3 fusion
transcript, inhibition of the Smad3 phosphorylation by halofugi-
none, an inhibitor of fibroblast-to-myofibroblast transition [26–
28], resulted in the reduction in tumor growth that was accompanied
by the inhibition of myofibroblast activation and reduction in TFE3
expression by the tumor cells.
Patient and Methods
Patients
Brain metastases were obtained from 18- and 20-year-old male
ASPS patients with thigh tumors and lung metastases. After the re-
moval of the primary tumors, one of the patients was clinically stable
with no therapy for 4 years, when a single brain metastasis was iden-
tified by magnetic resonance imaging and removed surgically. Addi-
tional brain metastasis appears during the next 2 years, despite
cranial irradiation. The second patient developed brainmetastasis soon
after diagnosis, and tissue was obtained from a resection. The pulmo-
nary biopsy was taken from a lower lobe of a 16-year-old female who
underwent a thoracotomy to lessen tumor burden. The primary tumor
at the left scapula developed tomultiple pulmonary nodules bilaterally.
Materials
Fetal calf serum, Dulbecco’s modified Eagle’s medium, and trypsin-
EDTA solution (0.02–0.25%) were obtained from Biochemical In-
dustries (Bet-HaEmek, Israel). Sirius red F3B was obtained from
BDH Laboratory Supplies (Poole, England). Halofuginone brom-
hydrate was obtained from Collgard Biopharmaceuticals Ltd (Tel
Aviv, Israel). Monoclonal antibodies to αSMA were from Dako A/S
(Glostrup, Denmark), and antibodies to cygb/STAP were a gift from
N. Kawada from the Department of Hepatology, Osaka City Univer-
sity, Japan. Smad3 antibodies were from Abcam (Cambridge, UK);
TFE3, mMET, phospho-Smad3, and SRF antibodies were from Santa
Cruz Biotechnology (Santa Cruz, CA).
Animals and Experimental Design
The human renal cell carcinoma cell line FU-UR-1 (a generous gift
fromDrMasako Ishiguro,Department of Pathology, FukuokaUniver-
sity School of Medicine, Fukuoka, Japan) with the reciprocal ASPL-
TFE3 fusion transcript [29] was cultured in Dulbecco’s modified
Eagle’s medium with 10% fetal calf serum. All animal experiments
were carried out according to the guidelines of the Volcani Center
Institutional Committee for Care and Use of Laboratory Animals.
Nude (CD1 nu/nu) male mice (Harlen Laboratories, Israel) were
housed in cages (four mice per cage) under conditions of constant pho-
toperiod (12-hour light/12-hour dark) with free access to food and
water. Xenografts were established by implanting the FU-UR-1 cells
in Matrigel (2 × 106 cells/ml) subcutaneously using a 27-gauge needle.
Halofuginone (5 μg per mouse) was administered intraperitoneally
three times a week starting at the time that the tumor volume reached
40mm3. During the experiments, tumor volume was determined with
a caliper according to the following formula: length × width × depth ×
0.5236; and it is presented as the mean ± SE.
Preparation of Sections, In Situ Hybridization,
and Immunohistochemistry
At the end of the experiments, tumors were collected and fixed
overnight in 4% paraformaldehyde in PBS at 4°C. Serial 5-μm sec-
tions were prepared from the xenograft tumors and from the ASPS
brain and lung metastases. Samples were stained with Sirius red for
collagen. In situ hybridization for collagen α1(I) was performed as
previously described [26]. Immunohistochemistry was performed
with anti–Cygb/STAP (1:500), monoclonal anti-αSMA antibodies
(1:200), Smad3 (1:200), TFE3 (1:100), mMET (1:50), phospho-
Smad3 (1:50), and SRF (1:500) antibodies. Peroxidase activity was
revealed by using 3,3′-diaminobenzidine as chromogen.
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Results
Alveolar Soft-Part Sarcoma Pulmonary and Brain Metastases
Tumor cells in both lung and brain metastases were large but
uniform, with abundant granular-to-vacuolated cytoplasm and
well-defined cell borders. The nuclei were round-to-polygonal and
vesicular, often with prominent nucleoli. The nuclei were positive
for TFE3, and in both the lung and the brain specimens, extensive
cell division was observed (Figure 1). In both pulmonary and brain
metastases, the stroma and the tumor cells were positive for prolifer-
ating cell nuclear antigen. No MET receptor tyrosine kinase expres-
sion was observed in the pulmonary and brain ASPS metastases (data
not shown), although it was identified in few malignancies with
TFE3 translocations and was significantly overexpressed in some pri-
mary ASPS tumors [30].
Stromal Components in ASPS Pulmonary Metastases
The cancer cells of the pulmonary metastasis were surrounded by
myofibroblasts that express the collagen α1(I) gene that resulted in
high levels of collagen synthesis (Figure 2). The collagen is organized
in fibrils that encircle clusters of cancer cells, which resulted in fi-
brous septa. No expression of the collagen α1(I) gene was observed
either in the surrounding lung tissue or in the primary tumor (data
not shown). The myofibroblasts also exhibited high levels of αSMA,
a hallmark of activated myofibroblasts as found in ASPS tumors from
other locations [31]. High levels of αSMA were also observed in the
blood vessels in the periphery of the metastasis. The cancer cells also
display characteristic components characteristic of the stroma. They
synthesized cytg/STAP that is usually expressed by myofibroblasts
from various origins [27,28] and prolyl 4-hydroxylase (P4H), one
of the major enzymes required for collagen cross-linking and matu-
ration (Figure 3). Both cytg/STAP and P4H were exclusively synthe-
sized by the tumor cells and not by the myofibroblasts within the
tumor or by the surrounding lung tissue.
Smad3 Signaling in ASPS Pulmonary Metastases
Serum response factor, which acts as a nuclear repressor of Smad3-
mediated TGFβ signaling, is essential for myofibroblast differentiation
Figure 1. Pulmonary and brain ASPS metastases. Hematoxylin and eosin staining shows an organoid, pseudoalveolar large round to
polyhedral eosinophilic cells displaying large nucleus with a uniform “small nest” pattern separated by fine fibrous septa (original mag-
nification, ×100; insert’s original magnification, ×40). The pulmonary and brain tumor cells express high levels of TFE3 (arrows; original
magnification, ×200). Both the metastatic cells and the stroma cells (arrows) stain positive for proliferating cell nuclear antigen (original
magnification, ×200) suggesting that they are at their proliferative state.
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[32]. Smad3, in turn, links TGFβ signaling to SRF-associated regu-
latory network [17]. The stromal cells within the pulmonary metasta-
sis, but not the tumor cells or the adjacent lung tissue, express SRF
(Figure 4). Transforming growth factor beta possesses dual tumor-
suppressive and oncogenic effects. During tumorigenesis, malignantly
transformed cells often lose the response to the tumor-suppressive
effects of TGFβ, which, in turn, starts to act as an autocrine tumor-
promoting factor by enhancing cancer invasion and metastasis. The
stroma cells within the neoplastic tissue and the lung epithelial
cells in the adjacent tissue stain positive for Smad3, whereas the
phosphorylated active form of Smad3 was found mostly in the tumor
cells, although some of the stromal cells exhibited phospho-Smad3
as well.
Alveolar Soft-Part Sarcoma Brain Metastases
The ASPS brain myofibroblasts, as detected by their ability to ex-
hibit αSMA, synthesize much less collagen than the pulmonary
ASPS cells, resulting in much thinner septa surrounding the tumor
cells (Figure 5). Similar to the pulmonary tumor cells, the metastatic
brain cancer cells express cytg/STAP, but in contrast to the lung me-
tastases, they also express SRF, Smad, and the phosphorylated active
form of Smad3. The same results were obtained from both ASPS
patients’ brain tumor specimens.
Inhibition of Tumor Growth Derived from Cells with
Reciprocal ASPL-TFE3 Fusion Transcript
Xenografts were established in the nude mice through subcutane-
ous implantation of FU-UR-1 renal carcinoma cell line that contain
the reciprocal ASPL-TFE3 fusion transcript [29]. In the untreated
mice, the tumors reached the volume of 277 mm3 at 33 days after
implantation (Figure 6A). Halofuginone, an inhibitor of myofibro-
blast activation and of Smad3 phosphorylation [28,33,34], inhibited
tumor growth and development and, at 33 days after cell implanta-
tion, had only grown to 38% of the volume of the control mice
(Figure 6A). The inhibition in tumor volume by halofuginone was
associated with the near complete reduction in TFE3 synthesis by
the tumor cells and with the reduction in activated myofibroblasts
as demonstrated by abrogation of collagen and αSMA synthesis
(Figure 6B). Halofuginone also inhibited SRF synthesis, and in
agreement with other studies [27,33,34], halofuginone inhibited
the phosphorylation of Smad3 without affecting Smad3 levels.
Discussion
Alveolar soft-part sarcoma is a rare and uncommon tumor with a
characteristic histopathology, and despite overall indolent clinical
behavior, patients eventually develop distant metastases [31]. The
ASPS lung and brain metastases consists of at least two cell types: the
Figure 2. Pulmonary ASPS metastases contain activated myofibroblasts. The myofibroblasts surrounding clusters of cancer cells ex-
press the collagen α1(I) gene (arrows) and synthesize large amounts of collagen (stained by Sirius red). These cells and the endothelial
cells of the blood vessels (BV) at the periphery of the metastasis synthesize αSMA as determined by immunohistochemistry. Original
magnifications: upper panel, ×40; lower panel, ×400.
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Figure 3. Pulmonary metastatic ASPS tumor cells express stromal components. The tumor cells, but not the stromal cells, synthesize
cygb/STAP and the β subunit of prolyl 4-hydroxylase (P4Hβ) as demonstrated by immunohistochemistry (arrows). CC indicates cancer
cells; S , stroma populated with myofibroblasts. Original magnifications: upper panel, ×100; lower panel, ×400.
Figure 4. Smad3 signaling in pulmonary ASPS metastasis. The myofibroblasts in the pulmonary metastasis, but not in the surrounding
lung tissue, exhibited SRF (arrows), whereas Smad3 is present both in the tumor stromal cells and lung epithelial cells. Phospho-Smad3
was demonstrated mostly in the tumor and some of the stroma cells but not by the lung epithelial cells. Original magnification, ×400.
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myofibroblasts and the ASPS tumor cells that express TFE3 (Figure 1)
with a probable cross talk between the two. The ASPS metastatic
myofibroblasts, like in other tumors [28,35], acquire muscle-specific
phenotype as demonstrated by high levels of αSMA, synthesize
high levels of ECM constituents especially collagen type I (Figure 2),
and demonstrate proliferation capabilities (Figure 1), all of which
are characteristic of activated myofibroblasts. The myofibroblasts
within the pulmonary ASPS tumor exhibited SRF (Figure 4), which
is a transcription factor that controls many mitogen-responsive and
muscle-specific genes such as αSMA and MyoD through the regu-
latory elements-CArG boxes in their promoter [36,37]. In the
brain, however, SRF is expressed by the tumor cells and not by
the stromal cells, although the stroma cells synthesized high levels
of αSMA (Figure 5), which may indicate a cross talk between the
two cell types. The tumor cells are most likely involved in the col-
lagen metabolism as well, which suggests again an intimate relation-
ship between the two cell types. They express P4H, an enzyme
required for collagen cross-linking (Figure 3), as was found in other
tumors [38,39]. The brain and lung metastatic tumor cells also ex-
pressed cygb/STAP (Figures 3 and 5) that is involved in collagen
metabolism as well [23]. It is interesting to note that the synthesis
of these two proteins is under the control of hypoxia [24,40].
Cygb/STAP is probably involved in cellular oxygen homeostasis
and supply and plays a role as an oxygen reservoir that is used under
hypoxic conditions. In contrast to many tissues and tumors in
which cygb/STAP is synthesized by the stroma cells [27,28,41],
in ASPS lung and brain metastases, only the cancer cells exhibited
high levels of cygb/STAP. Whether this localization of cytg/STAP is
unique to ASPS is still to be determined.
The origin of ASPS is controversial, and based on reports that
ASPS cells express muscle-specific genes such as αSMA, MyoD1,
and myogenin, it has been suggested that ASPS cells represent an un-
usual form of myogenic tumor [1,42,43]. Conversely, other studies
could not detect muscle-specific genes in ASPS tumors, which do not
support a myogenic origin [44–46]. Our findings suggest that the
muscle-specific genes observed in ASPS may, in certain cases, be as-
sociated with the stroma fibroblast-to-myofibroblast transition and
SRF function controlling muscle-specific gene transcription [17]
rather than with an indication of its origin. These myofibroblasts
that are unique mesenchymal cells with properties inherent to both
muscle and nonmuscle cells express skeletal muscle structural and
regulatory proteins. These include sarcomeric myosin heavy chain,
αSMA, and MyoD, and despite the presence of such myogenic reg-
ulatory proteins, these cells do not terminally differentiate into skel-
etal muscle [47].
Recently, overexpression of the MET receptor tyrosine kinase gene
was found in some ASPS primary tumors. It was demonstrated that
ASPL-TFE3 mediated transcriptional up-regulation of the MET re-
ceptor tyrosine kinase, which results in its autophosphorylation and
activation of downstream signaling in the presence of hepatocyte
growth factor. Thus, MET signaling was suggested as a target for
pharmacological intervention for ASPS patients [30]. The ASPS pul-
monary and brain metastases were negative for MET, suggesting that
different treatment strategies may be required for ASPS primary tu-
mors and metastases.
The myofibroblasts together with ECM components provide the
microenvironment that is pivotal for tumor cell growth, tumor inva-
sion, and metastasis [18]. Thus, inhibition of fibroblast activation may
become a viable approach for ASPS tumor treatment. Halofuginone,
which at present is being evaluated in clinical trials [48], inhibits the
fibroblast-to-myofibroblast transition of the tumor microenvironment
[28,49] by inhibiting Smad3 phosphorylation downstream of the
Figure 5. Stroma components and Smad signaling in the ASPS brain metastases. The tumor cells in the brain metastases are surrounded
by fibrous septa (A; original magnification, ×100) and populated by myofibroblasts displaying a large amount of αSMA (B; original mag-
nification, ×100). The tumor cells exhibited high levels of cytg/STAP (C; original magnification, ×100), SRF (D; original magnification, ×400)
Smad3 (E; original magnification, ×400), and phospho-Smad3 (F; original magnification, ×100; insert’s original magnification, ×400).
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TGFβ/SRF signaling [33,34]. Previously, we reported that targeting
the fibroblast-to-myofibroblast transition with halofuginone may
synergize with low doses of chemotherapy in achieving a significant
antitumoral effect, avoiding the need of a high dose of chemotherapy
and its toxicity without impairing treatment efficacy [28]. In xeno-
grafts that contain the reciprocal ASPL-TFE3 fusion transcript, halo-
fuginone inhibited myofibroblasts’ activation as demonstrated by the
abrogation of αSMA and collagen synthesis probably due to the
TGFβ/SRF-Smad3 signaling inhibition (Figure 6). This resulted in a
major decrease in tumor growth and development (Figure 6A). The
role of TGFβ in tumor development is controversial and may be de-
pendent on the origin of the tumor. Serum response factor, which is
part of the TGFβ signaling pathway, is implicated in cancer progres-
sion, specifically at the epithelial-mesenchymal transition [50,51].
Overexpression of SRF accelerates migration and invasion of tumor
cells with subsequent acquisition of mesenchymal phenotype and ac-
tivation of immediate early genes. We demonstrated that in ASPS me-
tastasis, Smad3 downstream of TGFβ and SRF were found in the
tumor cells and in the myofibroblasts. Thus, functional antagonism
of SRF or inhibition of Smad3 phosphorylation may provide a thera-
peutic approach by controlling tumor cell invasion and metastasis on
one hand and fibroblast-to-myofibroblast transition on the other.
Moreover, halofuginone treatment caused an almost complete inhibi-
tion in TFE3 synthesis by the tumor cells (Figure 6B). TFE3 has been
found to bind Smad3 and Smad4 and to synergistically trans-activate
the transcription of Smad7 in response to TGFβ [52]. Thus, TFE3-
Smad3 response elements may represent a common target for TGFβ-
induced gene expression, a feature that may be shared with various
TFE3 fusions including ASPS.
In conclusion, our data demonstrated for the first time the exis-
tence of the TGFβ/SRF–dependent Smad3 pathway and the pres-
ence of activated myofibroblasts in pulmonary and brain ASPS
metastases that may serve as a novel target for treatment of metastatic
lesions in ASPS.
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Figure 6. Inhibition of tumor growth in an ASPL-TFE3 fusion transcript xenografts by halofuginone. (A) Halofuginone treatment inhibited
tumor growth and development in xenografts derived from the FU-UR-1 cell with reciprocal ASPL-TFE3 fusion transcript. Insert: Tumors
of control and halofuginone-treated mice at 33 days after FU-UR-1 cell implantation. (B) Inhibition of TFE3, myofibroblasts’ activa-
tion, and Smad3 signaling in FU-UR-1 xenograft by halofuginone. At day 33 after FU-UR-1 cell implantation, tumors from control and
halofuginone-treated mice were taken for histopathology analysis. Almost all of the tumor cells of the untreated mice exhibit high levels
of TFE3, which was abrogated by halofuginone treatment (original magnification, ×400). Halofuginone treatment inhibited the collagen
and αSMA synthesis observed in the control mice (arrows; original magnification, ×200) suggesting inhibition of myofibroblasts’ acti-
vation. Halofuginone also inhibited the SRF and phosphorylation of Smad3 without affecting Smad3 levels (arrows; original magnifica-
tion, ×400).
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